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molecular neovascularization of the myocardium and
the enhancement of bypass graft patency. We will dis-
cuss the potential impact gene transfer and genetic engi-
neering principles and technologies may have on car-
diovascular surgery and on surgical outcomes. Finally,
rapid progress in human genome sequencing and map-
ping is likely to affect cardiovascular therapeutics and
surgery. We believe the integration of the disciplines of
gene therapy and genomics and cardiovascular surgery
should result in the emergence of a new field of therapy
that we term surgiomics.
Gene therapy strategies and delivery systems
Gene therapy is defined as any manipulation of gene
expression or function for the treatment of a specific
disease. This manipulation may be achieved either via
the introduction of foreign DNA into cells that encode
a biologically active transgene or through “transfec-
tion” of short chains of nucleic acids known as oligo-
deoxynucleotides (ODNs) that modify endogenous
gene expression in target cells (Fig 1). Gene transfer
can result in the expression and replacement of a miss-
ing gene product or in the “overexpression” of a native
or foreign gene whose product can prevent or reverse a
disease process. Many therapeutic settings will demand
some degree of control over the duration, location, and
level of transgene expression. To this end, researchers
have begun to develop gene promoter systems that
allow regulation of the spatial or temporal pattern of
gene expression. Gene blockade can be accomplished
by transfection of cells with either complementary
DNAs (cDNAs) encoding antisense or decoy se-
quences, or with antisense or decoy ODNs. Antisense
ODNs are generally 15 to 20 bases in length and are
designed to have a sequence that is complementary to a
segment of the target gene messenger RNA (mRNA).
By binding to the message, it renders the template
unavailable for translation into its biologically active
product.1 Alternately, decoy ODNs are double-stranded
chains designed to mimic the chromosomal binding
sites of transcription factors (factors that regulate gene
expression by binding to chromosomal DNA at specif-
ic promoter regions) and act as “decoys,” reducing the
availability of transcription factors required for subse-
quent activation or suppression of target genes.2
Another form of gene blockade is the use of
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Over the past decade, with the advent of moleculartechnologies, our understanding of the complex
mechanisms behind cardiovascular diseases has expand-
ed exponentially. From the identification of inherited
single gene disorders to multigenic acquired pathology,
the fundamental genetic contributions of these diseases
are unquestionable. These developments have led to an
enhanced interest in gene-based therapeutic strategies.
The ability to alter patterns of gene expression or func-
tion in an effort to correct or prevent disease processes
forms the basis for “gene therapy.” The delivery of
genetic agents and successful manipulation of gene
expression in living tissues has been crucial to the poten-
tial realization of this exciting technology.
The application of this technology not only will affect
the overall approach to medical therapies, but likely
will improve our ability to treat patients surgically.
Complications that limit the long-term efficacy of tradi-
tional surgical cardiovascular therapies, such as trans-
plantation and bypass grafting, will greatly benefit from
advances in both our understanding and treatment of the
genetic and molecular basis of these problems. In this
review, we will present the state of gene therapy strate-
gies and the range of methods for genetic intervention
that currently exist. We will review the progress and
application of this technology toward the improvement
of surgical cardiac revascularization, as it applies to
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“ribozymes,” segments of RNA that can act like
enzymes to destroy only specific sequences of target
mRNA. Ribozymes contain both a catalytic region that
can cleave other RNA molecules in a sequence-specif-
ic manner and an adjacent sequence that confers the
specificity of the target.
Although many cells will naturally take up DNA
from their extracellular environment in small amounts,
such low levels are generally insufficient to achieve a
physiologically significant influence on genetic func-
tion. Clinical gene therapies will therefore depend on
the development of vector systems that enhance the
efficiency of in vivo DNA transfer. The “ideal” vector
would be capable of safe and highly efficient delivery
to all cell types, both proliferating and quiescent, with
the opportunity to select either short-term or indefinite
gene expression. This ideal vector would also have the
flexibility to accommodate genes of all sizes, incorpo-
rate control of the temporal pattern and degree of gene
expression, and to recognize specific cell types for tai-
lored delivery or expression. Although progress is
being made on each of these fronts individually,
researchers remain far from possessing a single vector
with all of these characteristics. Instead, a spectrum of
vectors has evolved, each of which may find a niche in
different early clinical gene therapy strategies.
Viral vectors. Viruses are the most common vehicles
for exogenous gene delivery into mammalian cells.
Although they take on many distinct forms, all viruses
consist of a genetic nucleic acid code encapsulated in a
machinery that facilitates gene transfer and, in many
cases, gene expression. Recombinant viral particles
used as gene transfer vectors are distinguished from
their naturally occurring derivative viruses, most
importantly by their inability to replicate. This is
achieved by deletion or mutation of various genetic ele-
ments required for completion of the normal viral life
cycle. Instead, therapeutic genes are cloned into the
recombinant genome and coupled to the necessary reg-
ulatory elements.
Just as viral vectors appear to be nature’s solution to
the problem of efficient gene transfer, the true realiza-
tion of their technologic potential has been confounded
by the biologic barriers that have evolved to protect
Fig 1. Schematic representation of gene therapy strategies. A, Gene transfer. B, Gene blockade. TF, Transcription
factor.
cells and organisms from viral infection. Not only has
the host immunologic response limited the efficacy of
viral gene transfer, particularly when repeated adminis-
trations are considered, but the inflammatory response
to viral antigens has impeded and, at times, negated the
therapeutic benefits of transgene expression.3 En-
gineering of viral genomes does not always preclude
residual cytotoxicity in infected cells, and the possibil-
ity for regression to replication proficiency or for fur-
ther mutation and recombination with other virulent
viruses in the environment pose biologic hazards that
are difficult to quantitate or predict.
Retroviruses encode RNA-dependent DNA-poly-
merases, known as reverse transcriptases, that convert a
viral RNA genome to double-stranded DNA.4 The
DNA is then inserted into a host chromosome, where
stable transgene expression may be possible. For this
integration to take place, the infected cell must under-
go cell division within a short time after infection, thus
limiting the delivery of the DNA to replicating cells.
Lentiviruses are another class of retrovirus that can
integrate into the host genome in the absence of repli-
cation. Although this is an attractive alternative for
gene transfer into quiescent cardiovascular cells, safety
concerns remain concerning the use of these members
of the human immunodeficiency virus family; some
concern also exists over mutation into its pathogenic
phenotype. Unlike retroviruses, recombinant adeno-
viruses are capable of infecting nondividing cells and
have therefore become the most widely used viral vec-
tor for experimental in vivo gene transfer in animal
models of cardiovascular disease.5 The use of adenovi-
ral vectors has been associated with significant
immunologic and cytotoxic complications. The
immune response and the absence of gene integration
significantly limit gene expression, which rarely lasts
beyond 2 weeks after adenoviral gene transfer.
Researchers are therefore exploring removal of nearly
all adenoviral genes, creating “gutless” adenoviruses,
both to reduce the immunogenicity of the vector and to
increase the size of possible transgene insertions.
Adeno-associated virus is a human parvovirus that is
not able to replicate unless a helper virus, such as ade-
novirus or herpes virus, is present in the same cell.
Adeno-associated virus has not been linked to human
disease and can infect a wide range of target cells,
establishing a latent infection by integration into the
genome of the cell, thereby yielding stable gene trans-
fer. Unlike retroviruses, adeno-associated viruses can
infect nonreplicating cells. However, adeno-associated
virus is limited by its small size and hence the size of
transgene DNA that can be inserted. In addition, the
efficiency of adeno-associated virus vectors for in vivo
cardiovascular gene therapy remains to be determined.6
Nonviral vectors. Plasmids are circular chains of
DNA that were originally discovered as a natural
means of gene transfer between bacteria. Naked plas-
mids can also be used to transfer DNA into mammalian
cells. The direct injection of plasmid DNA into tissues
in vivo can result in transgene expression, although
being limited to a few millimeters surrounding the
injection site. Numerous nonviral methods are avail-
able to enhance the delivery of plasmid or oligonu-
cleotide DNA into cells in vitro, including calcium
phosphate, electroporation, and particle bombardment,
but have shown only limited efficiency in vivo. The
encapsulation of DNA in artificial lipid membranes
(liposomes), primarily cationic liposomes, can facili-
tate its uptake and cellular transport and provides flex-
ibility in substituting different transgene constructs in
comparison with the relatively complex process of con-
structing recombinant viral vectors. Other substances,
such as lipopolyamines and cationic polypeptides, are
now being investigated as potential vehicles for
enhanced DNA delivery for both gene transfer and
gene blockade strategies with ODN. Our collaborators
have developed a novel fusigenic-liposome–mediated
gene transfer that uses a combination of fusigenic pro-
teins of the Sendai virus (hemagglutinating virus of
Japan; HVJ) in conjunction with neutral liposomes.7
We8 have recently reported that the application of a
controlled pressurized environment to cardiovascular
tissue in a nondistending manner can enhance both
ODN and plasmid uptake and nuclear localization. This
method has been used for the efficient, ex vivo delivery
of DNA to both experimental and human vein grafts
and in heart transplantation models.
Advances in vector technology, along with the iden-
tification of critical pathogenic gene expression, has
led to the application of gene therapy technology in
animal models of disease in an effort to improve exist-
ing cardiovascular surgical therapies. Improved paten-
cy of bypass grafts, myocardial neovascularization, and
immunomodulation of cardiac grafts are direct exam-
ples of investigators’ attempts to improve current surgi-
cal therapies. Additionally, the application of these
technologies may lead to the introduction of cell-based
or genetic therapies for the treatment of heart failure as
an adjuvant therapy during surgical treatments.
Gene therapy for vein graft failure
The long-term success of surgical revascularization
in the lower extremity and coronary circulations has
been limited by significant rates of autologous vein
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vascular cell proliferation among samples brought back
to the laboratory for organ culture analysis. Primary
graft failure was defined in this study as graft occlu-
sion, graft revision, or evidence on ultrasonography of
a stenosis of greater than 75% at 12 months after
surgery in those patients who were not candidates for
revision. Although this study was not designed to
detect a statistically significant reduction in primary
failures, the enrollment of a large proportion of high-
risk grafts using poor-quality vein conduits led to an
overall event rate that allowed comparison of E2F
decoy grafts to untreated controls. Fewer failures were
observed in E2F decoy–treated grafts, and, unlike con-
trols, failures were not observed beyond the first 6
months after the operation (Fig 2). Although the effica-
cy of this approach requires further validation in large-
scale multicenter trials, this study demonstrates the
safety and feasibility of ex vivo gene therapy of bypass
grafts and suggests a possible stabilization of human
graft biology similar to that seen in experimental grafts.
The success of this study may have broader implica-
tions for other forms of native arterial atherosclerosis,
such as coronary artery disease, and offers an encour-
aging glimpse into the future applicability of this ther-
apeutic approach.
With the development of virus-mediated gene deliv-
ery methods, some investigators have begun to explore
the possibility of using these systems ex vivo in autol-
ogous vein grafts. Chen and colleagues10 demonstrated
the expression of the marker gene β-galactosidase
along the luminal surface and in the adventitia of 3-day
porcine vein grafts infected with a replication-deficient
adenoviral vector at the time of surgery. The vein seg-
ments were incubated in a high viral titer suspension
for approximately 2 hours before implantation. Others
have explored the use of a novel adenovirus-based
transduction system, in which adenoviral particles
were linked to plasmid DNA via biotin/ streptavidin–
transferrin/polylysine complexes. β-Galactosidase
expression was documented 3 and 7 days after surgery
in rabbit vein grafts that had been incubated for 1 hour
with complexes before grafting. Expression was again
greatest on the luminal surfaces of the grafts, although
the presence of transfected cells in the medial and
adventitial layers was also reported.
The feasibility of gene transfer in vein grafts has
therefore led to the investigation of potential thera-
peutic end points such as inhibition of neointimal
hyperplasia. In a rabbit vein graft model, intraopera-
tive transfection of the senescent cell–derived
inhibitor gene, a downstream mediator of the tumor
suppressor gene p53, using the HVJ-liposome sys-
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graft failure. No pharmacologic approach has been
successful at preventing long-term graft diseases such
as neointimal hyperplasia or graft atherosclerosis.
Gene therapy offers a new avenue for the modification
of vein graft biology that might lead to a reduction in
clinical morbidity from graft failures. Intraoperative
transfection of the vein graft also offers an opportuni-
ty to combine intact tissue DNA transfer techniques
with the increased safety of ex vivo transfection. A
number of studies have documented the feasibility of
ex vivo gene transfer into vein grafts using a variety of
vector systems.
The vast majority of vein graft failures have been
linked to the neointimal disease that is part of graft
remodeling after surgery. Although neointimal hyper-
plasia contributes to the reduction of wall stress in vein
grafts after bypass, this process can also lead to luminal
narrowing of the graft conduit during the first years
after operation. Furthermore, the abnormal neointimal
layer, with its production of proinflammatory proteins,
is believed to form the basis for an accelerated form of
atherosclerosis that causes late graft failure.
Given the proliferative basis of neointimal hyperpla-
sia, our group chose to target the cell cycle as a means
of limiting vein graft disease. Preliminary studies indi-
cated that blockade of at least two cell cycle genes suc-
ceeded in preventing significant neointima formation in
experimental grafts. We therefore tested a single, intra-
operative treatment of vein grafts with a decoy ODN
targeting the transcriptional factor E2F, known to be
critical in the up-regulation of cell cycle proteins.
These genetically engineered vein grafts resisted neoin-
timal hyperplasia for at least 6 months in the rabbit
model. Furthermore, these conduits were able to stabi-
lize wall stress in the absence of a neointima via a
process of medial hypertrophy and proved resistant to
diet-induced graft atherosclerosis. Abnormal endothe-
lial cell function, a significant contributor to graft fail-
ure, was also shown to be improved by ODN inhibition
of the neointimal disease process.
A small-scale prospectively randomized double-blind
trial of human vein graft treatment with E2F decoy
ODN was conducted in patients undergoing peripheral
bypass surgery.9 Efficient delivery of the ODN was
accomplished within 15 minutes during the operation
by placement of the graft after harvest in a device that
exposes the vessel to ODN in physiologic solution and
allows simultaneous application of a pressure of 300
mm Hg to all sides of the vessel, avoiding any potential
distention injury. This approach resulted in ODN deliv-
ery to greater than 80% of graft cells and effectively
blocked target cell cycle gene expression, as well as
tem, was found to partially inhibit neointima formation.
In an alternative approach, George and colleagues,11,12
using a replication-deficient adenovirus expressing tis-
sue inhibitor of metalloproteinase-1 or -2, were able to
demonstrate decreased neointimal changes in a
human saphenous vein organ culture model. In a
porcine carotid interposition vein graft model, this
same group demonstrated that overexpression of tis-
sue inhibitor of metalloproteinase-3, using a replica-
tion-deficient adenovirus, was able to limit neointi-
mal disease, further validating the therapeutic
potential of this strategy.13 Finally, adenovirus over-
expression of a nonphosphorylatable, constitutively
active Rb gene was also able to demonstrate a reduc-
tion in neointima formation.14 Beyond affecting local
graft biology, the overexpression of a secreted thera-
peutic protein by a transduced graft may lead to the
treatment of disease in tissues downstream to the
location of graft implantation, further expanding the
versatility of this bypass conduit.
Gene therapy for neovascularization
The identification and characterization of “angio-
genic” growth factors have created an opportunity to
attempt therapeutic “neovascularization” of tissue
rendered ischemic by occlusive disease in the native
arterial bed. Angiogenesis refers more strictly to the
sprouting of new capillary networks from pre-exist-
ing vascular structures, whereas vasculogenesis is the
de novo development of both simple and complex
vessels during embryonic development. Although
molecular factors can stimulate angiogenesis in vivo,
as clearly established in a number of animal models,
it is less certain that these molecules can induce the
development of larger, more complex vessels of
“neovasculogenesis” in adult tissues that would be
capable of carrying significantly increased bulk
blood flow. Nevertheless, the possibility of enhanc-
ing even microvascular collateralization as a “biolog-
ic” approach to the treatment of tissue ischemia has
sparked the beginning of human clinical trials in neo-
vascularization therapy.
After the first description of the angiogenic effect of
fibroblast growth factors (FGFs), an abundance of
“pro-angiogenic” factors was discovered to stimulate
endothelial cell proliferation, enhanced endothelial
cell migration, or both. Vascular endothelial growth
factor (VEGF) and two members of the FGF family,
acidic FGF (FGF-1) and basic FGF (FGF-2), have
received the most attention as potential therapeutic
agents for neovascularization. Much debate persists
regarding the preferred agent and the optimal route of
delivery for angiogenic therapy in the ischemic human
myocardium or lower extremity. VEGF may be the
most selective agent for stimulating endothelial cell
proliferation, although VEGF receptors are also
expressed on a number of inflammatory cells includ-
ing members of the monocyte-macrophage lineage.
This selectivity has been viewed as an advantage,
because the unwanted stimulation of fibroblasts and
vascular smooth muscle cells in native arteries might
exacerbate the growth of neointimal or atherosclerotic
lesions. Despite this theoretical selectivity, however,
the experimental use of VEGF in animal models has
been associated not only with capillary growth, but
also with the apparent stimulation of vascular smooth
muscle cell proliferation and an exacerbation of neoin-
timal hyperplasia after vascular injury. Furthermore,
increases in local myocardial VEGF levels, through
either direct gene delivery or implantation of geneti-
cally engineered myoblasts, has been shown to result
in the formation of angiomas rather than organized
capillary or vascular networks. The FGFs are believed
to be even more potent stimulators of endothelial cell
proliferation, but, as their name implies, are much less
selective in their pro-proliferative action as well.
Optimizing the route of drug delivery depends heavily
on the pharmacokinetic properties of the agent.
Angiogenesis, however, is a very complex biologic
process involving multiple cell types engaged in multi-
ple activities, including extracellular tissue dissolution
and remodeling, cell proliferation, cell migration, cell
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Fig 2. Kaplan-Meier comparison of time to graft failure
between E2F-decoy ODN and untreated groups. Human
saphenous vein grafts treated with E2F decoy ODN demon-
strated a reduction in primary failure rates when compared
with untreated grafts.
recruitment, and programmed cell death. The role of any
single agent must be understood within the complicated
orchestration of multiple signaling agents and effectors.
Despite the large amount of data that has become avail-
able in the past two decades, details of the cellular and
molecular mechanisms of angiogenesis remain poorly
understood. Still, it is believed that many of the known
angiogenic factors, including VEGF and the FGFs, are
exquisitely potent and would not, therefore, require large
or prolonged dosing regimens. These conclusions are
partly based on the results of in vivo experiments in
which a broad range of dosing strategies, from implanta-
tion of sustained release formulations to single intra-
arterial boluses, have been reported to induce similarly
successful increases in tissue perfusion.15
Preclinical studies of angiogenic gene therapy have
used a number of models of chronic ischemia. An
increase in capillary density was reported in an
ischemic rabbit hind limb model after VEGF adminis-
tration. These results did not differ significantly,
regardless of whether VEGF was delivered as a single
intra-arterial bolus of protein, plasmid DNA applied to
the surface of an upstream arterial wall, or direct injec-
tion of the plasmid into the ischemic limb. Direct injec-
tion of an adenoviral vector encoding VEGF also suc-
ceeded in improving regional myocardial perfusion and
ventricular fractional wall thickening at stress in a
model of chronic myocardial ischemia induced via
placement of a slowly occluding Ameroid constrictor
around the circumflex coronary artery in pigs.16 A
number of studies have demonstrated increased region-
al blood flow and improved myocardial contractility
after perivascular or intravascular delivery of FGF gene
transfer agents.15
A number of phase I safety studies have already been
reported in which angiogenic factors or the genes
encoding these factors have been administered to a
small number of patients.17 These studies have
involved either the use of angiogenic factors in patients
with peripheral vascular or coronary artery disease who
were not candidates for conventional revascularization
therapies, or the application of pro-angiogenic factors
as an adjunct to conventional revascularization. The
modest doses of either protein factors or genetic mate-
rial delivered in these studies were not clearly associat-
ed with any acute toxicities. Concerns remain, howev-
er, regarding the safety of potential systemic exposure
to molecules that are known to enhance the growth of
possible occult neoplasms or that can enhance diabetic
retinopathy and potentially even occlusive arterial dis-
ease itself. Despite early enthusiasm, there is also little
experience with the administration of live viral vectors
in extremely large numbers to a large number of
patients, and it is uncertain whether potential biologic
hazards of reversion to replication competent states or
mutation and recombination will eventually become
manifest. The results of two phase II studies investigat-
ing the intravascular delivery of either VEGF or FGF-4
have been reported and have failed to demonstrate a
statistically significant improvement in exercise toler-
ance over placebo. These studies may underscore the
critical nature of targeting effective delivery of these
agents in a human clinical setting.
The elucidation of neovascularization as an adaptive
and possibly therapeutic phenomenon in the setting of
ischemic disease has coincided with the development
of what at first seemed to be a simpler approach to
revascularization. Transmyocardial laser revasculariza-
tion (TMR) involves the application of a high-energy
laser beam to the epicardial surface of the heart so that
tissue vaporization leads to formation of a transmural
channel. A percutaneous approach has more recently
been developed in which an intraventricular catheter
delivers laser energy to the endocardial surface for the
creation of channels that pass most but not all of the
way through the heart wall. It was originally hoped that
these channels would remain patent and provide a
source of “direct” revascularization of the myocardium
from the ventricular chamber. Although improved
myocardial perfusion and function have been demon-
strated after TMR in animal models of chronic
ischemia, histologic analysis of animal and human
specimens has now established that these channels are
rapidly occluded via thrombosis and fibrosis. Instead,
an increased capillary network has been documented to
develop, and it is now widely believed that TMR stim-
ulates an angiogenic response. It is most likely that the
effect is part of a generalized “response to injury,” in
which inflammatory and healing processes stimulate
the growth of new vessels that may ameliorate the
underlying ischemic nature of the injured tissue.18
Prospective randomized clinical studies assessing the
effects of human TMR have reported outcomes ranging
from complete relief of anginal symptoms, along with
improvement in functional status and myocardial per-
fusion, to short-term reduction in anginal symptoms
without changes in myocardial function or perfusion 1
year after treatment.19,20
In light of the observations that TMR may stimu-
late multiple elements of the multifactorial machin-
ery for tissue neovascularization and that single
angiogenic factor therapy can successfully enhance
blood flow to ischemic tissues, we have hypothesized
that a combination of single factor gene transfer with
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TMR might synergistically yield an even stronger
therapeutic response than either therapy alone. To
test this theory of complimentary pro-angiogenic
mechanisms, we conducted a series of experiments in
collaboration with the cardiac surgery laboratory of
Lawrence Cohn at Brigham and Women’s Hospital.21
Among 35 pigs that had undergone placement of an
Ameroid constrictor on the circumflex artery, those
that subsequently received VEGFl65 gene therapy via
plasmid injection combined with TMR displayed a
greater normalization of load-dependent and -inde-
pendent contractility and of ventricular wall motion
than those that were treated with either VEGF gene
therapy or TMR alone (Fig 3).
In addition to issues of safety, it is also unclear
whether the clinical success of conventional revascu-
larization, which has involved the resumption of lost
bulk blood flow through larger conduits, will be repro-
duced via biologic strategies that primarily increase
microscopic collateral networks. Neovascularization is
a naturally occurring process, and the addition of a sin-
gle factor may not overcome the causes of an inade-
quate endogenous neovascularization response in
patients with myocardial and lower limb ischemia.
Despite these limitations, angiogenic gene therapy may
provide an alternative not currently available to a sig-
nificant number of patients with untreatable disease
and may offer an adjunct to traditional therapies that
improves their long-term outcomes.
Cell and genetic engineering of bioprosthetic grafts
Prosthetic materials, such as polytetrafluoroethylene
or Dacron fabric, have been limited in their long-term
use as small-caliber grafts due to their thrombogenic
surfaces. A bioengineering, cell-based strategy for
decreasing or eliminating this thrombogenicity may
therefore yield a small-caliber bioprosthetic graft capa-
ble of maintaining normal flow. Successful isolation of
endothelial cells and their seeding onto prosthetic
grafts in animal models has been well characterized.
Furthermore, it has been hypothesized that the function
of these endothelial cells can be enhanced via the trans-
Fig 3. Combined gene transfer and TMR. Schematic representation of chronic ischemia induced by placement of
an Ameroid constrictor around the circumflex coronary artery in pigs. Ischemic hearts that underwent TMR fol-
lowed by injection of plasmid-encoding VEGF demonstrated better normalization of myocardial function than
either therapy alone.
fer of biologically active genes before implantation
onto the graft surface. The first indication for the pos-
sible use of this strategy was presented by Wilson and
colleagues,22 who demonstrated successful endothe-
lialization of a prosthetic vascular graft with autolo-
gous endothelial cells transduced with a recombinant
retrovirus encoding the LacZ gene. Additionally, seed-
ing of transduced vascular smooth muscle cells into the
interstices of a polytetrafluoroethylene graft then lumi-
nally seeded with untreated endothelial cells revealed
stable expression of the reporter gene after 5 weeks.
For therapeutic purposes, the use of a biologically
active transgene in these systems has led to mixed
results. Given that thrombus formation is a primary
pathobiologic process responsible for the failure of
these grafts, genes expressing antithrombotic pro-
teins have been tested. Dunn and colleagues23 seeded
4-mm Dacron grafts with retrovirally transduced
endothelial cells encoding the gene for human tissue
plasminogen activator and implanted them into the
femoral and carotid circulation of sheep. The prote-
olytic action of tissue plasminogen activator resulted
in a decrease in seeded endothelial cell adherence,
with no improvement in surface thrombogenicity. In
a primate model of an arteriovenous graft, however,
seeding of endothelial cells retrovirally transduced to
secrete hirudin onto a 4-mm polytetrafluoroethylene
graft resulted in both decreased thrombus formation
and neointimal changes at the venous anastomosis.
The use of VEGF in this context also has potentially
significant therapeutic applications. VEGF, when
transduced into a limited number of endothelial cells
and placed on the graft surface, may promote
endothelial survival and replication and yield
improved and more rapid graft coverage with a non-
thrombogenic endothelial layer. Additionally, secre-
tion of VEGF could lead to angiogenesis distal to the
grafted area in what is likely to be an ischemic tissue
bed. Further studies are needed to determine the local
effect of VEGF secretion on endothelial cell prolifer-
ation along with distant angiogenic stimuli.
Until recently, the need to harvest autologous donor
tissue for target cells, coupled with the increased costs
and complexity of tissue culture, has largely limited this
strategy to experimental models. Recent reports have
demonstrated the feasibility of obtaining autologous
progenitor endothelial cells from the peripheral circula-
tion that, when placed in proper culture conditions, can
be stimulated to differentiate into functional endothelial
cells.24 With the advent of this new technology, it may
become feasible one day to develop functional biopros-
theses capable of use in patients undergoing coronary or
peripheral revascularization. In addition, such a cell and
genetically engineered bioprosthesis could be useful for
delivering factors that would enhance graft function and
survival and, furthermore, provide an avenue for
intravascular drug delivery.
Gene therapy for immunomodulation
Genetic manipulation of donor tissues offers the
opportunity to design organ-specific immunosuppres-
sion during cardiac transplantation. Although trans-
genic animals are being explored as potential sources
for immunologically protected xenografts, the delivery
of genes for immunosuppressive proteins, or the block-
ade of certain genes in human donor grafts, may allow
site-specific, localized immunosuppression and a re-
duction or elimination of the need for toxic systemic
immunosuppressive regimens. Gene activity has been
documented in transplanted mouse hearts for at least 2
weeks after intraoperative injection of the tissue with
either plasmid DNA or retroviral or adenoviral vectors.
The transfer of a gene for either transforming growth
factor-β or interleukin 10 in a small area of the heart
via direct injection in this model succeeded in inhibit-
ing cell-mediated immunity and delaying acute rejec-
tion. It has been shown that the systemic administration
of antisense ODN directed against intercellular adhe-
sion molecule-1 (ICAM-1), when combined with a
monoclonal antibody against the ligand for ICAM-1,
leukocyte function antigen-1 (LFA-1), also prolonged
graft survival and induced long-term graft tolerance.
This ICAM-1/LFA-1 blockade strategy was also suc-
cessful at inducing long-term tolerance and donor-spe-
cific suppressor T-cell activity via a single ex vivo,
pressure-mediated delivery of ICAM-1 antisense ODN
to the donor heart combined with a 6-day postoperative
course of systemic LFA-1 monoclonal antibody treat-
ment of host immune cells, providing support for an
organ-specific gene manipulation approach.25
Gene and cell therapy of heart failure
Failure of the myocardium due to insults such as
ischemia, infection, metabolic disorders, or substance
abuse afflicts millions annually. Functionally, a prin-
cipal defect of the failed myocardium is its ineffective
or weakened contractility. To this end, investigators
have explored the possibility of improving or revers-
ing this derangement by introducing directly and
overexpressing transgenes that can improve ventricu-
lar function or alter the molecular process of heart
failure. Another approach is the implantation of
myocardial cells that may be genetically engineered
to enhance myocardial function. These may be intro-
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duced at the time of surgery and may be an adjunct
therapy to cardiac surgery.
The β-adrenergic receptor is known to be a critical
player in mediating the inotropic state of the heart and
has shown to be down-regulated in failed myocardium.
As a result, it has received significant attention as a tar-
get for genetic therapeutic intervention in congestive
heart failure. Milano and colleagues,26 using trans-
genic mice overexpressing the β2-adrenergic receptor
exclusively in the myocardium, demonstrated an
approximately 200-fold increase in the level of β2-
adrenergic receptor along with highly enhanced con-
tractility and increased heart rates in the absence of
exogenous β-agonists. This genetic manipulation of
the myocardium has generated considerable interest in
the transfer of the β-adrenergic receptor gene into the
ailing myocardium as a means of therapeutic interven-
tion. Akhter and colleagues27 have demonstrated
improved contractility after adenovirus-mediated gene
transfer of the human β2-adrenergic receptor of rabbit
ventricular myocytes that had been chronically paced
to produce hemodynamic failure. Furthermore, they
were able to demonstrate improvement in myocardial
function after adenovirus-mediated overexpression of
human β2-adrenergic receptor delivered via the coro-
nary arteries in a rabbit heart failure model.28
There has also been recent interest in the enhance-
ment of contractility through the manipulation of
intracellular calcium levels. Sarcoplasmic reticulum
Ca2+-adenosinetriphosphatase (SERCA2a) transport-
ing enzyme, which regulates Ca2+ sequestration into
the sarcoplasmic reticulum, has also been shown to be
decreased in a variety of human and experimental car-
diomyopathies. Using adenovirus-mediated gene
transfer, Hajjar and colleagues29 were able to overex-
press the SERCA2a protein in neonatal rat cardiomy-
ocytes. This led to an increase in the peak [Ca2+]i
release, a decrease in resting [Ca2+]i levels, and more
importantly to enhanced contraction of the myocar-
dial cells as detected by shortening measurements.
Furthermore, using a replication-deficient adenovirus,
overexpression of SERCA2a in the myocardium of a
rat heart failure model led to restoration of both sys-
tolic and diastolic function.30 The success of this
approach to improving myocardial contractility has
yet to be documented in vivo but once again provides
a novel and potentially exciting means by which to
treat the failed heart.
At the cellular level, heart failure due to myocardial
infarction results from the loss of functional cardiomy-
ocytes that are subsequently replaced by a fibroblast-
rich scar tissue. Because cardiomyocytes are terminal-
ly differentiated, there is no regeneration of myocytes
to repopulate the area of injury after infarction.
Researchers have therefore pursued the possibility of
genetically converting cardiac fibroblasts into function-
al cardiomyocytes. The feasibility of this notion gained
support after in vitro expression of MyoD, a skeletal
muscle lineage-determining gene, converted cardiac
fibroblasts into cells resembling skeletal myocytes
using retrovirus-mediated gene transfer. Fibroblasts
expressing the MyoD gene were observed to develop
multinucleated myotubes, similar to those seen in stri-
ated muscle, which expressed major histocompatibility
complex and myocyte-specific enhancer factor-2.
Additionally, Murry and colleagues31 also showed
expression of myogenin and embryonic skeletal major
histocompatibility complex after transfection of rat
hearts injured by freeze-thaw with an adenovirus-con-
taining the MyoD gene. At this time, however, func-
tional cardiomyocytes have not yet been identified in
regions of myocardial scarring treated with in vivo
gene transfer. More recently, researchers have reported
that bone marrow stromal cells may contain cardiac
stem cells that can differentiate into adult cardiomyo-
cyte.32 These cells may be potentially harvested, cul-
tured, and implanted into the myocardium for thera-
peutic purposes.
Genomics and surgery
Research of the human genome including the
Human Genome Project and many other studies will
have a major and transforming impact on the under-
standing and conduct of biology, clinical medicine,
and therapeutics, including surgery.33 Expressed
sequence tags representing all sequences expressed in
humans will be determined and their genomic posi-
tions will be defined (sequence tagged sites). The dis-
covery of all the variants in the human genome that
contribute to the genetic diversity of the human popu-
lation will result in the construction of dense poly-
morphic maps. The rapid growth of databases of
expressed sequence tags, sequence tagged sites, and
single-nucleotide polymorphism, coupled with
impressive technologic advances, will surely have a
dramatic effect on biomedical research and clinical
medicine. An understanding of the genetic diversity
and how this diversity contributes to variations in nor-
mal and abnormal physiology will have a powerful
effect on medicine in the coming decades. It will be
technically feasible to genotype and analyze these
variants on an individual basis. It will be possible to
genotype at several thousand single-nucleotide poly-
morphic regions. The ability to rapidly genotype indi-
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viduals at high density will greatly enhance the abili-
ty to determine genes playing causal roles in the
development of disease on a population basis and pos-
sibly to predict which individuals will be susceptible
to disease and to better diagnose and treat disease.
The knowledge of the location of genes in the genome
will greatly enhance the ability of investigators to iden-
tify disease genes. Genetic analysis results in the defi-
nition of genomic regions linked to disease. With the
accumulations of mapped genes, the likelihood that
these regions will contain genes is growing. Indeed, the
likelihood of the disease gene of interest being listed
among these candidate expressed sequence tags in a
chromosomal region is rapidly escalating. The ability to
identify genes (even unknown genes) residing within an
interval linked to a particular disease, especially if the
tissue patterns of expression of these genes are known
or can be determined, will dramatically increase the
power of genetic analysis and more rapidly yield candi-
date genes for further analysis. The analysis of genetic
variations will be useful in the prediction, diagnosis, and
prognosis of disease. For example, the prognosis of a
complex disease that may be treated by surgery can be
determined with a high degree of accuracy through the
genotyping of a handful of genes. This will enable a
surgeon to determine the most appropriate time to per-
form surgery and to identify the subset of patients who
will respond positively to surgical intervention. The
power of this approach will be enhanced by the recent
technical advances that increase the ability to assess
genetic variants, for example, use of DNA microarrays.
In the context of cardiovascular disease, it may become
possible to identify patients more susceptible to stroke,
myocardial infarction, or renal disease and to treat these
individuals more aggressively. Moreover, it may
become possible to find subsets of patients who are
more susceptible to end-organ damage and who respond
differentially to surgery with a reduction in risk of end-
organ damage. Furthermore, genomics may be useful in
predicting and thus avoiding complications of surgery,
including tissue reactions, incompatibility, and rejec-
tion. Thus, genetic/genomic profiling may identify indi-
viduals at increased risk for surgical complications and
assist the surgeon in preoperative, intraoperative, and
postoperative management.
Finally, genomic studies will also enable the dis-
covery of new gene targets for therapy. As discussed
earlier, the application of gene therapy and genetic
engineering approaches has targeted known candi-
date genes whose inhibition or overexpression yields
therapeutic effects. However, these known candidate
genes are currently limited in number. In the future,
genomic research will discover many new genes that
can be manipulated in vivo or ex vivo to improve sur-
gical outcome.
Summary
The introduction of gene transfer, genetic engineer-
ing, and genomic principles and technologies may one
day enhance the tissue compatibility, durability, and
performance of surgical therapies for cardiovascular
disease. Furthermore, surgical implants may potential-
ly be used as sources for local or targeted therapeutic
gene products. These potential applications of sur-
giomics promise to expand the horizons of current sur-
gical therapies and extend the surgeons’ reach to the
level of cellular and molecular physiology. This syner-
gistic evolution of surgical and molecular science,
however, will require the close collaboration of experts
from a wide variety of biologic and medical sciences
and will help transform the practice of both medicine
and surgery in the 21st century.
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